AIM: This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country. PATIENTS AND METHODS: 24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored. RESULTS: Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin values normalized after 6 months and the platelet count increased to 147,818/mm3 after 18 months of treatment. Splenomegaly improved (mean 13.8x to 5.6x normal), hepatomegaly improved (mean 1.4x to 1.06x normal), the severity score decreased (mean 15.9 to 8.4), plasma chitotriosidase levels showed a reduction from 40,956 to 11,266 nmol/h per ml plasma. Bone disease improved clinically in all patients; bone radiography and osteodensitometry showed no further disease progress. We observed a mean weight gain of 4.3 kg, an improvement in quality of life, and the absence of therapeutic adverse events. CONCLUSIONS: Enzyme replacement therapy administered for 18 months in Romanian patients with Gaucher disease type I led to a marked improvement in haematological parameters and hepato- and splenomegaly. In the majority of patients we observed no further progress of bone disease; for an improvement in skeletal disease, a longer treatment period is required.
AIM: This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country. PATIENTS AND METHODS: 24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored. RESULTS: Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin values normalized after 6 months and the platelet count increased to 147,818/mm3 after 18 months of treatment. Splenomegaly improved (mean 13.8x to 5.6x normal), hepatomegaly improved (mean 1.4x to 1.06x normal), the severity score decreased (mean 15.9 to 8.4), plasma chitotriosidase levels showed a reduction from 40,956 to 11,266 nmol/h per ml plasma. Bone disease improved clinically in all patients; bone radiography and osteodensitometry showed no further disease progress. We observed a mean weight gain of 4.3 kg, an improvement in quality of life, and the absence of therapeutic adverse events. CONCLUSIONS: Enzyme replacement therapy administered for 18 months in Romanian patients with Gaucher disease type I led to a marked improvement in haematological parameters and hepato- and splenomegaly. In the majority of patients we observed no further progress of bone disease; for an improvement in skeletal disease, a longer treatment period is required.
Authors: Maaike de Fost; Carla E M Hollak; Johanna E M Groener; Johannes M F G Aerts; Mario Maas; Ludger W Poll; Maaike G Wiersma; Dieter Häussinger; Sarah Brett; Nicole Brill; Stephan vom Dahl Journal: Blood Date: 2006-03-09 Impact factor: 22.113
Authors: A El-Beshlawy; L Ragab; I Youssry; K Yakout; H El-Kiki; K Eid; I M Mansour; S Abd El-Hamid; M Yang; P K Mistry Journal: J Inherit Metab Dis Date: 2006-02 Impact factor: 4.982
Authors: R A Barneveld; W Keijzer; F P Tegelaers; E I Ginns; A Geurts van Kessel; R O Brady; J A Barranger; J M Tager; H Galjaard; A Westerveld; A J Reuser Journal: Hum Genet Date: 1983 Impact factor: 4.132
Authors: Neal J Weinreb; Mario C Aggio; Hans C Andersson; Generoso Andria; Joel Charrow; Joe T R Clarke; Anders Erikson; Pilar Giraldo; Jack Goldblatt; Carla Hollak; Hiroyuki Ida; Paige Kaplan; Edwin H Kolodny; Pramod Mistry; Gregory M Pastores; Ricardo Pires; Ainu Prakash-Cheng; Ainu Prakesh-Cheng; Barry E Rosenbloom; C Ronald Scott; Elisa Sobreira; Anna Tylki-Szymańska; Ashok Vellodi; Stephan vom Dahl; Rebecca S Wappner; Ari Zimran Journal: Semin Hematol Date: 2004-10 Impact factor: 3.851
Authors: Anca Zimmermann; Radu A Popp; Heidi Rossmann; Simona Bucerzan; Ioana Nascu; Daniel Leucuta; Matthias M Weber; Paula Grigorescu-Sido Journal: Ther Clin Risk Manag Date: 2018-10-24 Impact factor: 2.423